research use only
Cat.No.S2660
|
In vitro |
DMSO
: 89 mg/mL
(200.94 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 442.9 | Formula | C21H21ClF2O4S |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 471905-41-6 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C1CC(CCC1CCC(=O)O)(C2=C(C=CC(=C2)F)F)S(=O)(=O)C3=CC=C(C=C3)Cl | ||
| Features |
A moderately potent γ-secretase inhibitor.
|
|---|---|
| Targets/IC50/Ki |
Aβ
(in human SH-SY5Y cells) 5 nM
|
| In vitro |
MK-0752 is identified as a moderately potent γ-secretase inhibitor, which reduces Aβ40 in a dose-dependent manner with an IC50 of 5 nM in human SH-SY5Y cells. In vitro, this compound blocks Notch-intracellular domain (ICD) cleavage and its subsequent nuclear translocation.
|
| In vivo |
MK-0752 (240 mg/kg) reduces the generation of newly produced Aβ with 90% decrease of AUV in the brain of rhesus monkeys. In addition, this compound treatment increases levels of Aβ 1-14, Aβ 1-15, and Aβ 1-16 , while decreases levels of Aβ 1-17. In guinea-pigs, oral administration of this chemical (10 mg/kg -30 mg/kg) results in the dose-dependent reduction of Aβ40 in plasma, brain and cerebrospinal fluid (CSF) with IC50 of 440 nM in brain.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01295632 | Completed | Advanced Cancer |
Merck Sharp & Dohme LLC |
February 2011 | Phase 1 |
| NCT00572182 | Terminated | Brain and Central Nervous System Tumors |
Pediatric Brain Tumor Consortium|National Cancer Institute (NCI) |
July 2008 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Question 1:
Do you have the half-life information for it when used in cell culture?
Answer:
Its half-life in patients is about 15 hours, but in different cell culture it might be various, and we generally recommend replenishing with fresh drug every 24-48 hours.